Aerocrine AB (LTS:0O35) Total Assets : kr588.7 Mil (As of Mar. 2015)

View and export this data going back to . Start your Free Trial

What is Aerocrine AB Total Assets?

Aerocrine AB's Total Assets for the quarter that ended in Mar. 2015 was kr588.7 Mil.

Total Assets is connected with ROA %. Aerocrine AB's annualized ROA % for the quarter that ended in Mar. 2015 was -71.68%. Total Assets is also linked to Revenue through Asset Turnover. Aerocrine AB's Asset Turnover for the quarter that ended in Mar. 2015 was 0.13.

Aerocrine AB Total Assets Historical Data

The historical data trend for Aerocrine AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerocrine AB Total Assets Chart

Aerocrine AB Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Total Assets

Get a 7-Day Free Trial

350.98

244.81

304.28

379.58

230.87

Aerocrine AB Quarterly Data
	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15
Total Assets	Get a 7-Day Free Trial															324.06	294.87	240.82	230.87	588.67

Aerocrine AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Aerocrine AB's Total Assets for the fiscal year that ended in Dec. 2014 is calculated as

Total Assets	=	Total Equity (A: Dec. 2014 )	+	Total Liabilities (A: Dec. 2014 )
	=	-114.832	+	345.697
	=	230.9

Aerocrine AB's Total Assets for the quarter that ended in Mar. 2015 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2015 )	+	Total Liabilities (Q: Mar. 2015 )
	=	244.918	+	343.754
	=	588.7

Aerocrine AB (LTS:0O35) Total Assets Explanation

Total Assets is connected with ROA %.

Aerocrine AB's annualized ROA % for the quarter that ended in Mar. 2015 is

ROA %	=	Net Income (Q: Mar. 2015 )	/	( (Total Assets (Q: Dec. 2014 )	+	Total Assets (Q: Mar. 2015 ))	/ count )
	=	-293.72	/	( (230.865	+	588.672)	/ 2 )
	=	-293.72	/	409.7685
	=	-71.68 %

Note: The Net Income data used here is four times the quarterly (Mar. 2015) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Aerocrine AB's Asset Turnover for the quarter that ended in Mar. 2015 is

	Asset Turnover
=	Revenue (Q: Mar. 2015 )	/	( (Total Assets (Q: Dec. 2014 )	+	Total Assets (Q: Mar. 2015 ))	/ count )
=	53.171	/	( (230.865	+	588.672)	/ 2 )
=	53.171	/	409.7685
=	0.13

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Aerocrine AB Total Assets Related Terms

Thank you for viewing the detailed overview of Aerocrine AB's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Aerocrine AB (LTS:0O35) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aerocrine AB (LTS:0O35) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.aerocrine.com

Aerocrine AB is a medical technology company focused on improving the treatment of patients with inflamed airways. The company offers exhaled nitric oxide (NO) monitoring devices for research and clinical applications. Aerocrine's devices utilize methods for measuring minute concentrations of NO, and incorporate NO scrubbers to eliminate atmospheric NO from the patient's breath. Measuring NO values helps doctors differentiate asthma from similar conditions, and differentiate various forms of asthma from other airway diseases. The company markets two products globally namely NIOX Flex and NIOX MINO. These products are widely used by primary care asthma specialists in Europe, and have recently gained US regulatory approval. Distribution agreements have also been signed in Japan, and regulatory approval has been secured in China. The company has offices and subsidiaries in Sweden, Germany, the United States, and the United Kingdom. The parent company is located in Solna, Sweden, and has sales enterprises in Sweden, Germany, the United States, and the United Kingdom. NIOX was replaced by its successor, NIOX FLEX in 2007. NIOX FLEX was the first tailor-made device for measuring exhaled nitric oxide (NO). NIOX FLEX includes enhanced data handling facilities, add-on research kits, and USB ports for communication. Moreover, a new application, NIOX Flex Flow, can determine whether lung inflammation is located centrally or more peripherally, which can be highly significant to therapy choices. The Nasal Research Kit allows measurement of nasal NO, while the FlexFlo Research Kit enables measurement of exhaled NO at variable flow rates, to help identify the location of inflammation. NIOX MINO is a compact hand-held device, marketed for smaller clinics, healthcare centers, and hospitals. NIOX MINO is intended for routine measurements of NO. Patients hold the NIOX MINO and breathe into the mouthpiece. An audible tone helps patient maintain the right flow during exhalation, whereupon results are displayed on the front of the device.

Aerocrine AB (LTS:0O35) Headlines

No Headlines